Skip to main content
SpringerLink
Log in

Comparative Effectiveness, Personalized Medicine and Innovation

The Path Forward

  • Industry Perspectives
  • Comparative Effectiveness and Personalized Medicine
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. For patients, avoidance of unnecessary or unbeneficial therapies offers potentially far-reaching benefits, including avoidance of long-term complications and the worsening of a health condition or overall health.

  2. Although the possibility exists for faster and less expensive phase III trials, with reduced required trial sizes for personalized therapies for which biomarkers and/or companion diagnostics might be available, on the whole — and especially in early stages — development costs and timelines could actually increase.[6]

  3. The Genetic Information Nondiscrimination Act of 2008[9] is a newly implemented federal law that aims to protect individuals from being treated unfairly because of differences in their DNA that may affect their health. The law prevents discrimination from health insurers and employers. The law was crafted with the intent to help ease concerns about discrimination that might keep some people from getting genetic tests that could benefit their health. The law also enables people to take part in research studies without fear that their DNA information might be used against them in terms of their health insurance or in the workplace.

References

  1. The American Recovery and Reinvestment Act of 2009, HR1, 111th Cong.

  2. Patient Protection and Affordable Care Act of 2010, HR3590, 111th Cong.

  3. US Department of Health and Human Services. Federal Coordinating Council for Comparative Effectiveness Research. Report to the President and Congress, June 30, 2009. Washington, DC: US Department of Health and Human Services, 2009 [online]. Available from URL: http://www.hhs.gov/recovery/programs/cer/cerannualrpt.pdf [Accessed 2010 June 23]

    Google Scholar 

  4. US Department of Health and Human Services. Federal Coordinating Council for Comparative Effectiveness Research. Report to the President and Congress, June 30, 2009. Washington, DC: US Department of Health and Human Services, 2009 [online]. Available from URL: http://www.hhs.gov/recovery/programs/cer/cerannualrpt.pdf [Accessed 2010 June 23]

    Google Scholar 

  5. Garber A, Tunis S. Does comparative-effectiveness research threaten personalized medicine? [editorial]. N Engl J Med 2009 May 7; 360 (19): 1925–7

    Article  PubMed  CAS  Google Scholar 

  6. Garrison L, Finley Austin MJ. Linking pharmacogeneticsbased diagnostics and drugs for personalized medicine. Health Aff (Millwood) 2006 Sept/Oct; 25 (5): 1281–90

    Article  Google Scholar 

  7. Of NICE and men. Wall Street J 2010 July 7: A14

  8. Peel DC. Your medical records aren’t safe. Wall Street J 2010 Mar 13 [online]. Available from URL: http://online.wsj.com/article/SB10001424052748703580904575132111888664060.html [Accessed 2010 June 23]

    Google Scholar 

  9. The Genetic Information Nondiscrimination Act of 2008, Pub.L. 110-233, 110th Cong.

  10. Buto K, Juhn P. Can a center for comparative effectiveness information succeed? Perspectives from a health care company. Health Aff 2006 Nov/Dec; 25 (6): w586–8

    Google Scholar 

  11. Human genome project information [online]. Available from URL: http://www.ornl.gov/sci/techresources/Human_Genome/home.shtml [Accessed 2010 Jun 17]

  12. National Institute of General Medical Sciences. Pharmacogenetics Research Network [online]. Available from URL: http://www.nigms.nih.gov/Initiatives/PGRN [Accessed 2010 Jun 17]

    Google Scholar 

  13. Pharm GKB. International Warfarin Pharmacogenetics Consortium [online]. Available from URL: http://www.pharmgkb.org/views/project.jsp?pId=56 [Accessed 2010 Jun 17]

    Google Scholar 

  14. International Serious Adverse Events Consortium [online]. Available from URL: http://www.saeconsortium.org/ [Accessed 2010 Jun 17]

  15. Foundation for the National Institutes of Health. Biomarkers Consortium [online]. Available from URL: http://www.biomarkersconsortium.org/ [Accessed 2010 Jun 17]

    Google Scholar 

  16. Nelson GD. Perspective: preserving the milieu for medical innovation. Health Aff 1994; 13 (3): 112–4

    Article  CAS  Google Scholar 

  17. Gelijns A, Rosenberg N. The dynamics of technological change in medicine. Health Aff 1994; 13 (3): 28–46

    Article  CAS  Google Scholar 

  18. Phillips A. Looking backward to go forward. Next Generation Pharmaceutical 2009 Apr; 16 [online]. Available from URL: http://www.ngpharma.com/article/Looking-Backwardto-Go-Forward/ [Accessed 2010 Mar 4]

    Google Scholar 

  19. Meckley LM, Neumann PJ. Personalized medicine: factors influencing reimbursement. Health Policy 2010 Feb; 94 (2): 91–100

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors are all employees of, and shareholders in, Johnson & Johnson.

No external sources of funding were used to assist in the preparation of this article.

The authors extend a special thank you to Jami Taylor for her invaluable assistance in research and in the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Market Access, Johnson & Johnson Pharmaceutical Services LLC, Raritan, New Jersey, USA

    Adrian Thomas

  2. Biopharmaceutical Public Policy and Advocacy, Johnson & Johnson Government Affairs and Policy, Washington, DC, USA

    Audrey Phillips PhD

  3. Health Policy, Johnson & Johnson, Washington, DC, USA

    Robert Donnelly

  4. Health Economics and Outcomes Research, Centocor Ortho Biotech Services LLC, Titusville, New Jersey, USA

    Catherine Tak Piech

Authors
  1. Adrian Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Audrey Phillips PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert Donnelly
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Catherine Tak Piech
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thomas, A., Phillips, A., Donnelly, R. et al. Comparative Effectiveness, Personalized Medicine and Innovation. Pharmacoeconomics 28, 923–930 (2010). https://doi.org/10.2165/11539030-000000000-0000010.2165/11537370-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11539030-000000000-0000010.2165/11537370-000000000-00000

Keywords

Search

Navigation